Targeting B cells in SLE: good news at last!

被引：0

作者：

Iñaki Sanz

机构：

[1] Immunology and Rheumatology,Division of Allergy, Department of Medicine

[2] University of Rochester School of Medicine and Dentistry,undefined

来源：

Nature Reviews Rheumatology | 2011年 / 7卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

After a half-century wait, a new drug has been approved for the treatment of systemic lupus erythematosus. The success of belimumab could bolster the feasibility of B-cell-targeted approaches to treating the disease.

引用

页码：255 / 256

页数：1

共 8 条

[1]

Navarra SV(2011)Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 721-731

[2]

Manzi S(2010)Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and -76 studies [abstract 1456] Arthritis Rheum. 62 S607-1178

[3]

Wallace DJ(2009)A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus Arthritis Rheum. 61 1168-711

[4]

Yurasov S(2005)Defective B cell tolerance checkpoints in systemic lupus erythematosus J. Exp. Med. 201 703-210

[5]

Jacobi AM(2010)Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study Arthritis Rheum. 62 201-140

[6]

Blair PA(2010)CD19 Immunity 32 129-3325

[7]

Yang M(2010)CD24 J. Immunol. 184 3321-541

[8]

Iwata Y(2011)CD38 Blood 117 530-undefined

← 1 →